Document is current
Any future updates will be listed below
-
Authors
Sverstad, Alexander
Kristianslund, Olav
Petrovski, Goran
Moe, Morten Carstens
Jørstad, Øystein Kalsnes
-
Funding
Funding for this research was provided by:
University of Oslo
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 28 September 2024
First Online: 10 October 2024
Declarations
:
: Not applicable.
: Not applicable.
: A.S. has no competing interest to declare. O.K.: AbbVie (recipient) and Santen (recipient). G.P.: AbbVie (consultant), Bulbitech (consultant), Profundus (consultant), RetinaRISK (consultant), and Roche (consultant). M.C.M.: Bayer (consultant, recipient), Novartis (consultant), Roche (consultant, recipient), Apellis (consultant), and SJJ Solutions (consultant, recipient, patent share). Ø.K.J.: Allergan (consultant, recipient), Bayer (consultant, recipient), Roche (consultant), and SJJ Solutions (consultant, recipient, patent share).
